ReviewJournal of clinical medicine2020
Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.
- Biomolecular and Genetic Prognostic Factors That Can Facilitate Fertility-Sparing Treatment (FST) Decision Making in Early Stage Endometrial Cancer (ES-EC): A Systematic Review.International journal of molecular sciences · 2022Pooled it
- A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.Gynecologic oncology · 2023Trial
- Endometriosis and Endometrial Cancer-Association Between Biological Mechanisms and Its Clinical Implications.Journal of clinical medicine · 2026Review
- A Risk Prediction Model for Progression-Free Survival in Endometrial Cancer Integrating Clinicopathological Variables and Routine Laboratory Indicators.International journal of women's health · 2026Article
- Article
- Clinical Utility of Pan-Immune Inflammation Value (PIV) in Predicting Prognosis of Endometrial Cancer.Journal of clinical medicine · 2025Article
- Cell state dynamics during early stages of serous endometrial carcinoma.The Journal of pathology · 2025Article
- Evaluating Radiotheranostic Targets for Endometrial Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Racial differences in endometrial cancer genomics and outcomes using UNCseqGynecologic oncology reports · 2025Article
- Bioinformatics Analysis Identifies Lipid Droplet-Associated Gene Signatures as Promising Prognostic and Diagnostic Models for Endometrial Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
- Review
- Transferrin Receptor Promotes Endometrial Cancer Proliferation by Activating the Iron-Dependent PI3K/AKT/mTOR Signaling Pathway.Cancer science · 2025Article
- Synergistic anticancer effects of cisplatin and phenolic aglycones of the aerial part of Rumex dentatus L. in tongue squamous cell carcinoma: insights from network pharmacology and biological verification.BMC complementary medicine and therapies · 2025Article
- Estimation of TP53 mutations for endometrial cancer based on diffusion-weighted imaging deep learning and radiomics features.BMC cancer · 2025Article
- Mitochondria-related genes as prognostic signature of endometrial cancer and the effect of MACC1 on tumor cells.PloS one · 2025Article
- Immunohistochemistry as a reliable predictor of remission in patients with endometrial cancer: Establishment and validation of a machine learning model.Oncology letters · 2025Article
- RAB17 promotes endometrial cancer progression by inhibiting TFRC-dependent ferroptosis.Cell death & disease · 2024Article
- Prognostic Significance of Disseminated Tumor Cells in Bone Marrow for Endometrial Carcinoma Patients.Journal of clinical medicine · 2024Article
- ARG1 Is a Potential Prognostic Marker in Metastatic Endometrial Cancer.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities.NAR cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Endometrial cancer (EC) is the sixth most common cancer in women worldwide and its mortality is directly associated with the presence of poor prognostic factors driving tumor recurrence. Stratification systems are based on few molecular, and mostly clinical and pathological parameters, but these systems remain inaccurate. Therefore, identifying prognostic EC biomarkers is crucial for improving risk assessment pre- and postoperatively and to guide treatment decisions. This systematic review gathers all protein biomarkers associated with clinical prognostic factors of EC, recurrence and survival. Relevant studies were identified by searching the PubMed database from 1991 to February 2020. A total number of 398 studies matched our criteria, which compiled 255 proteins associated with the prognosis of EC. MUC16, ESR1, PGR, TP53, WFDC2, MKI67, ERBB2, L1CAM, CDH1, PTEN and MMR proteins are the most validated biomarkers. On the basis of our meta-analysis ESR1, TP53 and WFDC2 showed potential usefulness for predicting overall survival in EC. Limitations of the published studies in terms of appropriate study design, lack of high-throughput measurements, and statistical deficiencies are highlighted, and new approaches and perspectives for the identification and validation of clinically valuable EC prognostic biomarkers are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.